James N.'s most recent trade in Avidia Bancorp Inc. was a trade of 50,190 Stock Options done . Disclosure was reported to the exchange on Sept. 16, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avidia Bancorp Inc | James N. Ball | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 50,190 | 50,190 | - | - | Stock Options | |
| Avidia Bancorp Inc | James N. Ball | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 20,076 | 20,076 | - | 0 | Common Stock | |
| Corcept Therapeutics Inc | James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 110.27 per share. | 15 Sep 2026 | 6,800 | 1,067,743 (0%) | 0% | 110.3 | 749,835 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 111.70 per share. | 15 Sep 2026 | 2,800 | 1,064,543 (0%) | 0% | 111.7 | 312,771 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 110.84 per share. | 15 Sep 2026 | 400 | 1,067,343 (0%) | 0% | 110.8 | 44,335 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 111.44 per share. | 14 Aug 2026 | 4,668 | 1,076,822 (0%) | 0% | 111.4 | 520,214 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 110.49 per share. | 14 Aug 2026 | 3,053 | 1,081,490 (0%) | 0% | 110.5 | 337,341 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 112.64 per share. | 14 Aug 2026 | 2,279 | 1,074,543 (0%) | 0% | 112.6 | 256,706 | Common Stock |
| Cintas | James N. Rozakis | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2026 | 35,995 | 35,995 | - | - | Stock Option (Right to Buy) | |
| Cintas | James N. Rozakis | President & COO | Grant, award, or other acquisition of securities at price $ 202.71 per share. | 10 Aug 2026 | 10,695 | 285,808 (0%) | 0% | 202.7 | 2,167,983 | Common Stock |
| Cintas | James N. Rozakis | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2026 | 5,988 | 5,988 | - | - | Stock Option (Right to Buy) | |
| Cintas | James N. Rozakis | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 202.71 per share. | 10 Aug 2026 | 4,041 | 282,322 (0%) | 0% | 202.7 | 819,151 | Common Stock |
| Cintas | James N. Rozakis | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 202.71 per share. | 10 Aug 2026 | 3,643 | 282,720 (0%) | 0% | 202.7 | 738,473 | Common Stock |
| Cintas | James N. Rozakis | President & COO | Grant, award, or other acquisition of securities at price $ 202.71 per share. | 10 Aug 2026 | 555 | 286,363 (0%) | 0% | 202.7 | 112,504 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 87.74 per share. | 15 Jul 2026 | 3,969 | 1,089,495 (0%) | 0% | 87.7 | 348,223 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 88.81 per share. | 15 Jul 2026 | 2,974 | 1,086,521 (0%) | 0% | 88.8 | 264,122 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 89.49 per share. | 15 Jul 2026 | 1,978 | 1,084,543 (0%) | 0% | 89.5 | 177,007 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 86.78 per share. | 15 Jul 2026 | 1,079 | 1,093,464 (0%) | 0% | 86.8 | 93,633 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 83.57 per share. | 16 Jun 2026 | 5,823 | 1,094,543 (0%) | 0% | 83.6 | 486,633 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 82.69 per share. | 16 Jun 2026 | 4,177 | 1,100,366 (0%) | 0% | 82.7 | 345,416 | Common Stock |
| General Dynamics | James N. Mattis | Director | Grant, award, or other acquisition of securities at price $ 359.84 per share. | 16 Jun 2026 | 58 | 3,618 (0%) | 0% | 359.8 | 20,871 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 May 2026 | 892,056 | 9,011 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 May 2026 | 9,011 | 1,104,543 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 May 2026 | 9,011 | 0 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | James N. Wilson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Phathom Pharma Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2026 | 24,122 | 66,718 (0%) | 0% | 0 | Common Stock | |
| California Resources Corp - Ordinary Shares - New | James N. Chapman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 3,091 | 52,251 (0%) | 0% | 0 | Common Stock | |
| Avidia Bancorp Inc | James N. Ball | Director | Purchase of securities on an exchange or from another person at price $ 20.60 per share. | 27 Apr 2026 | 5,000 | 50,000 | - | 20.6 | 103,000 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Apr 2026 | 2,000 | 1,095,532 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Apr 2026 | 5,000 | 1,097,532 (0%) | 0% | 0 | Common Stock | |
| FinWise Bancorp | James N. Giordano | Director | Grant, award, or other acquisition of securities at price $ 15.73 per share. | 31 Mar 2026 | 3,179 | 399,607 | - | 15.7 | 50,006 | Common Stock, par value $0.001 per share |
| Corcept Therapeutics Inc | James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Mar 2026 | 4,000 | 1,102,532 (0%) | 0% | 0 | Common Stock | |
| General Dynamics | James N. Mattis | Director | Grant, award, or other acquisition of securities at price $ 354.31 per share. | 17 Mar 2026 | 105 | 3,560 (0%) | 0% | 354.3 | 37,203 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Mar 2026 | 28,000 | 1,106,532 (0%) | 0% | 0 | Common Stock | |
| General Dynamics | James N. Mattis | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 359.80 per share. | 09 Mar 2026 | 83 | 3,455 (0%) | 0% | 359.8 | 29,863 | Common Stock |
| CoastalSouth Bancshares Inc | James N. Richardson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2026 | 868 | 868 | - | - | Restricted Stock Units | |
| Corcept Therapeutics Inc | James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2025 | 400,000 | 1,045,168 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | James N. Wilson | Director | Other type of transaction at price $ 0.00 per share. | 12 Dec 2025 | 200,000 | 200,000 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | James N. Wilson | Director | Other type of transaction at price $ 0.00 per share. | 12 Dec 2025 | 200,000 | 200,000 (0%) | 0% | 0 | Common Stock | |
| Avidia Bancorp Inc | James N. Ball | Director | Purchase of securities on an exchange or from another person at price $ 16.13 per share. | 01 Dec 2025 | 5,000 | 45,000 | - | 16.1 | 80,656 | Common Stock |
| NewAmsterdam Pharma Co NV | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 23.70 per share. | 15 Sep 2025 | 660 | 3,028,524 | - | 23.7 | 15,639 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 24.99 per share. | 08 Sep 2025 | 1,260 | 3,027,864 | - | 25.0 | 31,487 | Ordinary Shares |
| FinWise Bancorp | James N. Giordano | Director | Purchase of securities on an exchange or from another person at price $ 19.32 per share. | 05 Sep 2025 | 2,500 | 2,500 | - | 19.3 | 48,300 | Common Stock, par value $0.001 per share |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2025 | 23,326 | 23,326 | - | - | Stock Option (Right to Buy) | |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 97.22 per share. | 11 Aug 2025 | 16,900 | 276,421 (0%) | 0% | 97.2 | 1,643,018 | Common Stock |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 16,900 | 16,900 | - | - | Stock Option (Right to Buy) | |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 99.46 per share. | 11 Aug 2025 | 13,884 | 278,760 (0%) | 0% | 99.5 | 1,380,903 | Common Stock |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 13,884 | 27,772 | - | - | Stock Option (Right to Buy) | |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.77 per share. | 11 Aug 2025 | 11,545 | 264,876 (0%) | 0% | 223.8 | 2,583,425 | Common Stock |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.77 per share. | 11 Aug 2025 | 9,563 | 269,197 (0%) | 0% | 223.8 | 2,139,913 | Common Stock |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 73.39 per share. | 11 Aug 2025 | 8,272 | 280,271 (0%) | 0% | 73.4 | 607,082 | Common Stock |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 8,272 | 0 | - | - | Stock Option (Right to Buy) | |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.99 per share. | 11 Aug 2025 | 6,920 | 276,117 (0%) | 0% | 62.0 | 428,971 | Common Stock |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 6,920 | 0 | - | - | Stock Option (Right to Buy) | |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Grant, award, or other acquisition of securities at price $ 223.88 per share. | 11 Aug 2025 | 6,852 | 259,521 (0%) | 0% | 223.9 | 1,534,026 | Common Stock |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.68 per share. | 11 Aug 2025 | 5,158 | 275,113 (0%) | 0% | 223.7 | 1,153,741 | Common Stock |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.70 per share. | 11 Aug 2025 | 4,118 | 271,999 (0%) | 0% | 223.7 | 921,197 | Common Stock |
| NewAmsterdam Pharma Co NV | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 23.98 per share. | 11 Aug 2025 | 471 | 3,026,604 | - | 24.0 | 11,294 | Ordinary Shares |
| Cintas | James N. Rozakis | Exec. Vice President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.56 per share. | 25 Jul 2025 | 3,859 | 252,669 (0%) | 0% | 223.6 | 862,718 | Common Stock |
| CoastalSouth Bancshares Inc | James N. Richardson | Director | Purchase of securities on an exchange or from another person at price $ 21.50 per share. | 02 Jul 2025 | 20,000 | 128,891 | - | 21.5 | 430,000 | Common Stock |
| NewAmsterdam Pharma Co NV | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 18.43 per share. | 24 Jun 2025 | 2,520 | 3,024,873 | - | 18.4 | 46,454 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 18.26 per share. | 24 Jun 2025 | 1,260 | 3,026,133 | - | 18.3 | 23,012 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 19.50 per share. | 16 Jun 2025 | 8,584 | 3,022,153 | - | 19.5 | 167,381 | Ordinary Shares |
| Corcept Therapeutics Inc | James N. Wilson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 25,000 | 25,000 | - | - | Stock option (right to buy) | |
| Phathom Pharma Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharma Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 10,500 | 42,596 (0%) | 0% | 0 | Common Stock | |
| FinWise Bancorp | James N. Giordano | Director | Grant, award, or other acquisition of securities at price $ 14.70 per share. | 27 May 2025 | 2,721 | 396,428 | - | 14.7 | 39,999 | Common Stock, par value $0.001 per share |
| Phathom Pharma Inc | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 3.86 per share. | 21 May 2025 | 3,780 | 59,403 (0%) | 0% | 3.9 | 14,609 | Common Stock |
| Phathom Pharma Inc | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 3.32 per share. | 13 May 2025 | 6,300 | 55,623 (0%) | 0% | 3.3 | 20,919 | Common Stock |
| Phathom Pharma Inc | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 3.16 per share. | 13 May 2025 | 1,120 | 49,323 (0%) | 0% | 3.2 | 3,543 | Common Stock |
| Phathom Pharma Inc | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 3.19 per share. | 09 May 2025 | 33,376 | 33,376 (0%) | 0% | 3.2 | 106,563 | Common Stock |
| Phathom Pharma Inc | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 3.04 per share. | 09 May 2025 | 12,601 | 48,203 (0%) | 0% | 3.0 | 38,301 | Common Stock |
| Phathom Pharma Inc | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 3.62 per share. | 09 May 2025 | 2,226 | 35,602 (0%) | 0% | 3.6 | 8,053 | Common Stock |
| California Resources Corp - Ordinary Shares - New | James N. Chapman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2025 | 5,698 | 49,160 (0%) | 0% | 0 | Common Stock | |
| Cintas | James N. Rozakis | Executive Vice President & COO | Sale of securities on an exchange or to another person at price $ 190.37 per share. | 07 Apr 2025 | 2,000 | 256,528 (0%) | 0% | 190.4 | 380,740 | Common Stock |
| NewAmsterdam Pharma Co NV | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 22.49 per share. | 26 Mar 2025 | 1,135 | 3,013,569 | - | 22.5 | 25,521 | Ordinary Shares |
| California Resources Corp - Ordinary Shares - New | James N. Chapman | Director | Purchase of securities on an exchange or from another person at price $ 45.59 per share. | 21 Mar 2025 | 17 | 43,462 (0%) | 0% | 45.6 | 775 | Common Stock |
| California Resources Corp - Ordinary Shares - New | James N. Chapman | Director | Purchase of securities on an exchange or from another person at price $ 39.42 per share. | 05 Mar 2025 | 2,000 | 43,445 (0%) | 0% | 39.4 | 78,840 | Common Stock |
| General Dynamics | James N. Mattis | Director | 05 Mar 2025 | 1,370 | 1,370 | - | - | Stock Options | ||
| General Dynamics | James N. Mattis | Director | 05 Mar 2025 | 330 | 3,268 (0%) | 0% | 0 | Common Stock | ||
| NewAmsterdam Pharma Co NV | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 21.02 per share. | 04 Mar 2025 | 4,005 | 3,012,434 | - | 21.0 | 84,203 | Ordinary Shares |
| General Dynamics | James N. Mattis | Director | 03 Mar 2025 | 81 | 2,938 (0%) | 0% | 254.1 | 20,583 | Common Stock | |
| Corcept Therapeutics Inc | James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Jan 2025 | 7,800 | 1,445,168 (1%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | James N. Wilson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.29 per share. | 22 Jan 2025 | 250,000 | 250,000 (0%) | 0% | 3.3 | 822,500 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2025 | 250,000 | 0 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | James N. Wilson | Director | Other type of transaction at price $ 0.00 per share. | 22 Jan 2025 | 146,742 | 1,452,968 (1%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Jan 2025 | 146,742 | 0 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | James N. Wilson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.03 per share. | 22 Jan 2025 | 103,258 | 146,742 (0%) | 0% | 59.0 | 6,095,320 | Common Stock |
| Corcept Therapeutics Inc | James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Dec 2024 | 7,800 | 1,306,226 (1%) | 0% | 0 | Common Stock | |
| Cintas | James Rozakis N. | Executive Vice President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 9,321 | 9,321 | - | - | Stock Option (right to buy) | |
| Cintas | James Rozakis N. | Executive Vice President & COO | Grant, award, or other acquisition of securities at price $ 759.63 per share. | 12 Aug 2024 | 2,689 | 64,632 (0%) | 0% | 759.6 | 2,042,645 | Common Stock |
| Cintas | James Rozakis N. | Executive Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 388.86 per share. | 31 Jul 2024 | 4,224 | 62,136 (0%) | 0% | 388.9 | 1,642,545 | Common Stock |
| Cintas | James Rozakis N. | Executive Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2024 | 4,224 | 8,450 | - | - | Stock Option (right to buy) | |
| Cintas | James Rozakis N. | Executive Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2024 | 4,056 | 0 | - | - | Stock Option (right to buy) | |
| Cintas | James Rozakis N. | Executive Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 260.79 per share. | 31 Jul 2024 | 4,056 | 63,132 (0%) | 0% | 260.8 | 1,057,764 | Common Stock |
| Cintas | James Rozakis N. | Executive Vice President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 765.68 per share. | 31 Jul 2024 | 3,060 | 59,076 (0%) | 0% | 765.7 | 2,342,981 | Common Stock |
| Cintas | James Rozakis N. | Executive Vice President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 765.38 per share. | 31 Jul 2024 | 2,558 | 60,574 (0%) | 0% | 765.4 | 1,957,842 | Common Stock |
| Cintas | James Rozakis N. | Executive Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2024 | 2,068 | 2,068 | - | - | Stock Option (right to buy) | |
| Cintas | James Rozakis N. | Executive Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 293.56 per share. | 31 Jul 2024 | 2,068 | 63,297 (0%) | 0% | 293.6 | 607,082 | Common Stock |
| Cintas | James Rozakis N. | Executive Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2024 | 1,730 | 1,730 | - | - | Stock Option (right to buy) | |
| Cintas | James Rozakis N. | Executive Vice President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 247.96 per share. | 31 Jul 2024 | 1,730 | 62,304 (0%) | 0% | 248.0 | 428,971 | Common Stock |